BAN2401-G000-201: A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

Conditions

Alzheimer´s Disease

What is the purpose of this trial?

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BAN2401 in subjects with early Alheimer's disease.


Participation Guidelines

Age:
50 Years - 90 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Eisai Pharmaceuticals
Dates:
05/30/2013
Last Updated:
Study HIC#:
1211011120